BACKGROUND: Real-world data on the long-term use of guselkumab for treatment of psoriasis are still limited. OBJECTIVE: We aimed to evaluate long-term efficacy, safety, and drug survival of guselkumab in a real-world setting. METHODS: This is a retrospective study analyzing Czech Republic registry (BIOREP) data of patients treated with guselkumab. RESULTS: In total, 333 patients were included. Improvement in Psoriasis Area and Severity Index (PASI) score was significant. Mean PASI score decreased from 16 at baseline to 0.7, 0.9, and 0.8 after 12, 24, and 36 months, respectively. Absolute PASI scores of ≤ 3 and ≤ 1 were achieved in 93.9% and 77.9%, 94.2% and 71.0%, and 94.8% and 70.7% of patients after 12, 24, and 36 months, respectively. Response PASI 90 and PASI 100 were attained in 81.8% and 57.1%, 75.4% and 50.7%, and 75.9% and 55.2% of patients after 12, 24, and 36 months, respectively. The percentage of patients achieving PASI 90 and PASI 100 responses was higher throughout the study in bio-naive and in normal-weight patients, while presence of psoriatic arthritis had no influence. Improvement in Dermatology Life Quality Index (DLQI) score was also significant; mean DLQI score decreased from 14.2 at baseline to 0.9, 1.0, and 0.7 after 12, 24, and 36 months, respectively. Patients with PASI 100 had lower mean DLQI throughout the study compared with patients with PASI 90. Major reason for discontinuation was loss of effectiveness in 7.1% of patients, while only 0.6% were due to adverse events. Overall cumulative drug survival was high, with only a minimal decline over time, reaching 91.6%, 87.0%, and 85.5% after 12, 24, and 36 months, respectively. Drug survival was not affected by previous biological treatment, patient weight, or presence of psoriatic arthritis. CONCLUSIONS: This real-world study demonstrated the long-term effectiveness, good safety profile, and high drug survival of guselkumab treatment over a period of 36 months.

Department of Dermatovenereology 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Department of Dermatovenereology 3rd Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady Prague Czech Republic

Value Outcomes Prague Czech Republic

Zobrazit více v PubMed

Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. doi: 10.1101/cshperspect.a015354. PubMed DOI PMC

Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. doi: 10.1016/S0190-9622(99)70112-X. PubMed DOI

Woo YR, Park CJ, Kang H, Kim JE. The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic. Int J Mol Sci. 2020;21(19):7041. doi: 10.3390/ijms21197041. PubMed DOI PMC

Srivastava AK, Chand Yadav T, Khera HK, et al. Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities. J Autoimmun. 2021;118:102614. doi: 10.1016/j.jaut.2021.102614. PubMed DOI

Pastor-Fernández G, Mariblanca IR, Navarro MN. Decoding IL-23 signaling cascade for new therapeutic opportunities. Cells. 2020;9(9):2044. doi: 10.3390/cells9092044. PubMed DOI PMC

Gooderham MJ, Papp KA, Lynde CW. Shifting the focus—the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119. doi: 10.1111/jdv.14868. PubMed DOI PMC

Nogueira M, Torres T. Guselkumab for the treatment of psoriasis—evidence to date. Drugs Context. 2019;9(8):212594. PubMed PMC

Light JG, Su JJ, Feldman SR. Clinical utility of guselkumab in the treatment of moderate-to-severe plaque psoriasis. Clin Cosmet Investig Dermatol. 2021;15(14):55–63. doi: 10.2147/CCID.S235242. PubMed DOI PMC

Kojanova M, Fialova J, Cetkovska P, et al. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int J Dermatol. 2017;56(4):428–434. doi: 10.1111/ijd.13543. PubMed DOI

Korman NJ, Malatestinic W, Goldblum OM, et al. Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient's perspective. J Dermatol Treat. 2022;33(2):733–739. doi: 10.1080/09546634.2020.1772454. PubMed DOI

Del Alcázar E, López-Ferrer A, Martínez-Doménech Á, et al. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022;35(2):e15231. PubMed

Peláez Bejarano A, Robustillo Cortés MA, Villar SP. Guselkumab in moderate-to-severe plaque psoriasis: effectiveness in real clinical practice. Rev Chil Dermatol. 2020;36(3):93–97.

Benhadou F, Ghislain PD, Guiot F, et al. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(12):e837–e839. doi: 10.1111/jdv.16715. PubMed DOI

Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021;85(4):1028–1030. doi: 10.1016/j.jaad.2021.01.025. PubMed DOI

Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2):e14798. doi: 10.1111/dth.14798. PubMed DOI

Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl) 2022;14(12):205–212. PubMed PMC

Amatore F, Villani AP, Tauber M, Viguier M, Guillot B, Psoriasis Research Group of the French Society of Dermatology French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483. doi: 10.1111/jdv.15340. PubMed DOI PMC

Gerdes S, Bräu B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854–1862. doi: 10.1111/1346-8138.16128. PubMed DOI

Mälkönen T, Nuutinen P, Hallinen T, et al. Guselkumab treatment outcomes and persistence in a nationwide real-world cohort of patients with plaque psoriasis. Acta Derm Venereol. 2022;102:adv00631. doi: 10.2340/actadv.v101.910. PubMed DOI PMC

Torres T, Puig L. Treatment goals for psoriasis: should PASI 90 become the standard of care? Actas Dermosifiliogr. 2015;106(3):155–157. doi: 10.1016/j.ad.2014.10.001. PubMed DOI

Wade R, Sharif-Hurst S, Dias S. Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. Syst Rev. 2020;9:132. doi: 10.1186/s13643-020-01395-6. PubMed DOI PMC

Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22:567–579. doi: 10.1007/s40257-021-00598-4. PubMed DOI

Zweegers J, Otero ME, van den Reek JM, et al. Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: a systematic review. Acta Derm Venereol. 2016;96(4):453–458. doi: 10.2340/00015555-2276. PubMed DOI

Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170. doi: 10.3390/jcm9072170. PubMed DOI PMC

Fougerousse AC, Ghislain PD, Reguiai Z, et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol. 2020;34(10):e644–e646. doi: 10.1111/jdv.16511. PubMed DOI

Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018;13:e0195123. doi: 10.1371/journal.pone.0195123. PubMed DOI PMC

Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford) 2016;55(12):2191–2199. doi: 10.1093/rheumatology/kew326. PubMed DOI

Zafiriou E, Daponte AI, Siokas V, Tsigalou C, Dardiotis E, Bogdanos DP. Depression and obesity in patients with psoriasis and psoriatic arthritis: is IL-17-mediated immune dysregulation the connecting link? Front Immunol. 2021;21(12):699848. doi: 10.3389/fimmu.2021.699848. PubMed DOI PMC

Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):CD011535. PubMed PMC

Hung YT, Lin YJ, Chiu HY, Huang YH. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice. Ther Adv Chronic Dis. 2021;29(12):20406223211046685. PubMed PMC

Bardazzi F, Viviani F, Merli Y, et al. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience. Expert Opin Biol Ther. 2022;13:1–6. PubMed

Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaçi D. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. Eur J Dermatol. 2012;22(6):762–769. doi: 10.1684/ejd.2012.1863. PubMed DOI

Oguz Topal I, Baysak S, Altunay İK, et al. Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study. An Bras Dermatol. 2022;97(5):566–574. doi: 10.1016/j.abd.2021.11.002. PubMed DOI PMC

Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019;81(2):427–432. doi: 10.1016/j.jaad.2019.02.062. PubMed DOI

Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM. Brodalumab is associated with high rates of complete clearance and quality of life improvement: a subgroup analysis of patients with psoriasis and concomitant psoriatic arthritis. Dermatology. 2022;238(4):620–629. doi: 10.1159/000520290. PubMed DOI PMC

Greb JE, Garber C, Gottlieb AB. Effect of psoriatic arthritis on treatment response in patients with moderate to severe psoriasis. J Drugs Dermatol. 2016;15(8):917–922. PubMed

Huang H, Cai ML, Hong XJ, et al. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients. Eur J Dermatol. 2020;30(5):554–560. doi: 10.1684/ejd.2020.3878. PubMed DOI

Rompoti N, Katsimbri P, Kokkalis G, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019;32(5):e13006. doi: 10.1111/dth.13006. PubMed DOI

Bonifati C, Capoccia R, Graceffa D, Morrone A. Effectiveness of systemic therapies in patients with obesity and psoriasis: a single-center retrospective study. Acta Dermatovenerol Croat. 2021;29(2):88–93. PubMed

Mastorino L, Susca S, Megna M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022;35(5):e15378. doi: 10.1111/dth.15378. PubMed DOI PMC

Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917–925. doi: 10.1007/s40261-021-01080-z. PubMed DOI PMC

Malara G, Trifirò C, Bartolotta A, et al. Real-world effectiveness and safety of guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci. 2021;25(1):406–412. PubMed

Dapavo P, Siliquini N, Mastorino L, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatol Treat. 2022;33(4):2352–2357. doi: 10.1080/09546634.2021.1961998. PubMed DOI

Iznardo H, Vilarrasa E, López-Ferrer A, Puig L. Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol. 2021;185(3):660–662. doi: 10.1111/bjd.20416. PubMed DOI

Lytvyn Y, Zaaroura H, Mufti A, AlAbdulrazzaq S, Yeung J. Drug survival of guselkumab in patients with plaque psoriasis: a 2 year retrospective, multicenter study. JAAD Int. 2021;8(4):49–51. doi: 10.1016/j.jdin.2021.05.003. PubMed DOI PMC

Van Muijen ME, Thomas SE, Vellinga D, et al. Real-world data reveal long drug survival for guselkumab in patients with plaque psoriasis. Acta Derm Venereol. 2022;102:adv00755. doi: 10.2340/actadv.v102.685. PubMed DOI PMC

Li Y, Lu JJ, Zhong XY, et al. Drug survival outcomes associated with the real-world use of ixekizumab, secukinumab, guselkumab, and adalimumab for the treatment of plaque psoriasis in China: a 52-week single-center retrospective study. Clin Cosmet Investig Dermatol. 2022;20(15):2245–2252. doi: 10.2147/CCID.S387759. PubMed DOI PMC

Zweegers J, van den Reek JM, van de Kerkhof PC, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175(2):340–347. doi: 10.1111/bjd.14552. PubMed DOI

Kojanova M, Hugo J, Velackova B, et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors—brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatol Treat. 2022;33(6):2827–2837. doi: 10.1080/09546634.2022.2082354. PubMed DOI

Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G. The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments. Vaccines (Basel) 2020;8(4):728. doi: 10.3390/vaccines8040728. PubMed DOI PMC

Ghislain PD, Failla V, Lambert J, et al. Effectiveness and tolerability of guselkumab in patients with psoriasis: a longitudinal Belgian retrospective multicenter study. JAAD Int. 2021;1(4):15–17. doi: 10.1016/j.jdin.2021.05.001. PubMed DOI PMC

Jung SW, Lim SH, Jeon JJ, Heo YW, Choi MS, Hong SP. Comparison of the efficacy and safety of biologics (secukinumab, ustekinumab, and guselkumab) for the treatment of moderate-to-severe psoriasis: real-world data from a single Korean center. Biomedicines. 2022;10(5):1058. doi: 10.3390/biomedicines10051058. PubMed DOI PMC